用于成本核算的输入成本参数

数据集获取（Figshare）

• 源站标题：Input cost parameters used for costing.
• DOI：10.1371/journal.pdig.0000894.t001
• 发布日期：2025-06-11
• 文件数：1 个
• 文件总体积：9.73 KB
• 源站页面：https://plos.figshare.com/articles/dataset/Input_cost_parameters_used_for_costing_/29296915

命令行下载

curl -L -o "Table 1.xls" "https://ndownloader.figshare.com/files/55314157"

文件清单

• Table 1.xls（9.73 KB）

文件总体积 9.73 KB（源站 API 实测）。

数据说明

Availability of ultraportable chest x-ray (CXR) and advancements in artificial intelligence (AI)-enabled CXR interpretation are promising developments in tuberculosis (TB) active case finding (ACF) but costing and cost-effectiveness analyses are limited. We provide implementation cost and cost-effectiveness estimates of different screening algorithms using symptoms, CXR and AI in Nigeria. People 15 years and older were screened for TB symptoms and offered a CXR with AI-enabled interpretation using qXR v3 (Qure.ai) at lung health camps. Sputum samples were tested on Xpert MTB/RIF for individuals reporting symptoms or with qXR abnormality scores ≥0.30. We conducted a retrospective costing using a combination of top-down and bottom-up approaches while utilizing itemized expense data from a health system perspective. We estimated costs in five screening scenarios: abnormality score ≥0.30 and ≥0.50; cough ≥ 2 weeks; any symptom; abnormality score ≥0.30 or any symptom. We calculated total implementation costs, cost per bacteriologically-confirmed case detected, and assessed cost-effectiveness using incremental cost-effectiveness ratio (ICER) as additional cost per additional case. Overall, 3205 people with presumptive TB were identified, 1021 were tested, and 85 people with bacteriologically-confirmed TB were detected. Abnormality ≥ 0.30 or any symptom (US$65704) had the highest costs while cough ≥ 2 weeks was the lowest (US$40740). The cost per case was US$1198 for cough ≥ 2 weeks, and lowest for any symptom (US$635). Compared to baseline strategy of cough ≥ 2 weeks, the ICER for any symptom was US$191 per additional case detected and US$ 2096 for Abnormality ≥0.30 OR any symptom algorithm. Using CXR and AI had lower cost per case detected than any symptom screening criteria when asymptomatic TB was higher than 30% of all bacteriologically-confirmed TB detected. Compared to traditional symptom screening, using CXR and AI in combination with symptoms detects more cases at lower cost per case detected and is cost-effective. TB programs should explore adoption of CXR and AI for screening in ACF.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pdig.0000894.t001（source: https://plos.figshare.com/articles/dataset/Input_cost_parameters_used_for_costing_/29296915）。